Drugmaker

This pharma company from Mumbai may be helping Putin get Nvidia AI chips

But this inconspicuous pharmaceutical company is part of a lucrative trade in leading-edge technology to Russia that has the US and its European allies worried at India's burgeoning role

EU approves Sanofi's Dupixent injection to treat chronic lung disease

The EU Commission approved Dupixent to treat chronic obstructive pulmonary disease (COPD) in patients that cannot be helped by standard inhaled drugs

EU top court rejects drugmaker Servier appeal against EU antitrust fine

The European Commission handed down the 331 million euro ($354 million) fine in 2014 to Servier, as well as fines to generic drugmakers Teva, Unichem and its subsidiary Niche, Matrix

Drugmakers to see FY25 revenue boost in key US market: India Ratings

The world's largest drug market is facing decade-high drug shortages, the research firm said in a note citing data from with Utah Drug Information Service

Novo Nordisk's major shareholder plans to invest about $35 bn by 2030

For Novo Holdings, which invests in life science companies and had assets of 108 billion euros ($115.86 billion) at end-2022, its recent investment in India was its largest in Asia to date

IndiaMART working with Novo Nordisk to halt illegal Wegovy sales: Report

IndiaMART, one of India's top online marketplaces, allows dealers to sell on its website after a nominal background check and says it has minimal control over what is advertised and sold

Novo Nordisk India head eyes 2026 Wegovy launch, warns against copycats

He urged patients not to buy copycat versions of Wegovy, warning they could be unsafe

DCGI issues advisory as US-based Abbott recalls batches of Digene gel

The DCGI has cautioned against the consumption of Abbott's antacid Digene gel citing safety concerns, even as the US-based drugmaker recalled several batches of the medicine manufactured at its Goa facility. According to a letter by the Drugs Controller General of India (DCGI), it was reported on August 9 that a bottle of Digene Gel (mint flavour), batch no 51030307, used by customers was of regular taste (sweet) and light pink in colour whereas another bottle of the same batch was of white colour with bitter taste and pungent odour as per a complaint. "Accordingly, M/s Abbott India Limited, Verna Industrial Estate, Salcette, Goa- vide letter dated August 11, 2023, informed DCGI office for voluntary recall of impugned product Digene Mint flavour batch no 51030307 and Digene Gel orange having batch no 50035107, 50035207, 50035307, 50035407 and voluntary stopped production of all variants of Digene Gel manufactured at their Goa facility," the DCGI letter stated. Further, Abbott India

Novo Nordisk is Europe's most valuable firm after launching obesity drug

The company's share price closed up 0.7 per cent to DKK 1,311 ($190), giving the company a market capitalisation of $428 billion

Drugmaker asked to stop production after non-standard quality samples: Govt

A Punjab-based drugmaker was asked to stop all manufacturing activities after samples collected from its premises, following an alert by the WHO, were found to be "not of standard quality", the Lok Sabha was informed on Friday. Minister of State for Health Bharati Pravin Pawar, in a written reply in the Lower House of Parliament, said the World Health Organization (WHO) issued a medical product alert for a batch of India-made Guaifenesin syrup in the Marshall Islands and the Federated States of Micronesia. Subsequent to the reports, the Central Drugs Standard Control Organisation (CDSCO) in coordination with State Drugs Authority, Punjab, conducted a joint investigation at M/s QP Pharmachem Ltd in Punjab. "Drug samples drawn from the manufacturing premises under the provisions of Drugs and Cosmetics Act, 1940 for test and analysis were declared as 'not of standard quality'," the minister said. "Further, the State Licensing Authority has directed the firm to stop all manufacturing .

India suspends another drugmaker's licence over tainted cough syrup

India has suspended a drugmaker's manufacturing licence after the World Health Organization flagged contamination in its cough syrups found in the Mashall Islands and Micronesia in April

Ajanta Pharma looks to expand ops in high-growth Asian, African geographies

As part of its growth plans, Ajanta Pharma is looking to enhance its presence across select geographies with high growth potential in Asia and Africa. In its Annual Report for 2022-23, the Mumbai-based drug maker stated that it intends to rely on its strengths to grow faster in countries where it has a presence with its range of branded generics. "As we achieve formidable positions in many markets, our strategy now entails enhancing focus on select countries from our geographical presence, which promises high growth potential," Ajanta Pharma informed its shareholders. These territories offer a large branded generics pharma market size, but the company's presence still remains small, it added. "We plan to ramp up our presence in these markets and add value to the patients' choices through our differentiated product portfolio," the drug firm said. The company's branded generics business accounted for 73 per cent of its revenues in FY 2023, with Indian, rest of Asia and Africa ...

Race to develop weight-loss pills has some drugmakers falling behind

Novo and Lilly's experimental obesity pills helped people lose about 15% of body weight, similar to weight-loss shots on the market already, according to findings presented

Indian drugmaker denies toxicity in paracetamol syrup exported to Liberia

Nigeria's National Agency for Food and Drugs Administration and Control said that samples of the Indian-made paracetamol suspension, Para Clear, exported to Liberia contained toxin ethylene glycol

2 more Indian drugmakers under lens in Nigeria for 'contamination'

Nigerian health agency flags off paracetamol, cough syrup

Kerala Minister estimates around Rs 8 cr loss in Kollam drug warehouse fire

Kerala Health Minister Veena George on Thursday said medicines and materials, worth around Rs 8 crore, were destroyed during a fire that gutted a warehouse of the state-run Kerala Medical Services Corporation Limited (KMSCL) in Kollam district last night. The district drug warehouse of KMSCL in Kollam was engulfed in fire on Wednesday night. It was a major supply source for medicines at state-run hospitals and PHCs in the district. There were no casualties in the incident. "The total loss due to the fire is estimated at Rs 8 crore. But the corporation need not suffer this much loss as the medicines are insured," she said. A comprehensive probe would be conducted into the reasons that led to the massive fire, she told reporters here. A scientific investigation report at various levels should be carried out to know how the blaze started, George said.

Sun Pharmaceuticals to see drop in revenue owing to IT security incident

Indian drugmaker Sun Pharmaceutical Industries Ltd would see a revenue drop in a few of its businesses and incur some expenses due to an IT security incident that happened earlier this month

Price is the key growth driver of Indian pharma market, shows AWACS data

Market set to grow by 2.5-5% in calendar 2022. could even hit 5% due to a strong seasonal sales such as anti-infectives, and impact of NLEM drugs price hike

Contract drug maker V-Ensure gets Rs 130 cr from Investcorp, Tanas Capital

Founded in 2010, V-Ensure is into specialty pharmaceutical formulations focused on complex generics for regulated markets

Drugmaker Merck has strong fourth quarter as Covid-19 treatment debuts

The blockbuster cancer treatment Keytruda pushed Merck past fourth-quarter expectations, and the drugmaker's COVID-19 treatment debuted with nearly $1 billion in sales. Sales for the Gardasil vaccine, which protects against cancer-causing human papilloma virus infections, jumped 50%, Merck said Thursday. Merck earned $3.75 billion in the final quarter of 2021 and sales jumping 24% to $13.52 billion. Adjusted earnings, which exclude items like interest expense, totalled $1.80 per share, far exceeding Wall Street's per-share projections of $1.53, according to a survey by the data firm FactSet. Merck sales also topped the quarterly revenue expectations of $13.16 billion from industry analysts. The drugmaker expects adjusted earnings of $7.12 to $7.27 per share on $56.1 billion to $57.6 billion in revenue. Wall Street has been projecting earnings of $7.30 per share on $56.71 billion in revenue. Shares of Merck & Co., based in Kenilworth, New Jersey, slipped 17 cents to $81.84 in ear